Oral Cancer Risk Assessment
Early Detection is Key
Early detection of cancer is the cornerstone of improving outcomes in cancer care. Advances in biomarkers, molecular technology, and artificial intelligence are the driving technological aids that provide solutions for the early detection of cancer. The expectation is that better diagnostic options will lead to earlier, more accurate, and targeted specific disease treatment.
9th Most Common Cause of Cancer Deaths
Oral cancer is the seventh most common neoplasm and the ninth most common cause of cancer death globally. Survival rates for oral cancer vary based on the time of diagnosis and disease progression. Unfortunately, current standard-of-care methodologies to identify oral cancer such as direct visualization of lesions and tactile techniques are ineffective. As a result, this disease is essentially asymptomatic until the latter stages where patients eventually experience pain, discomfort, bleeding or difficulty swallowing.
Cancer Staging vs. Survival Rates
The five-year overall survival rate in the U.S. for oral squamous cell carcinoma (OSCC) is 84% if diagnosed at an early stages of the disease (i.e., Stage I or II). However, more than 70% of oral cancer diagnoses are not made until the disease is in stage III or IV. At these later stages, the five year survival rate for OSCC specifically drops to less than 50%. Unfortunately, only 28% of patients with oral cancer in the U.S. are diagnosed at an early stage, when the cancer is localized, treatable and the 5-year survival is high. In addition, the prevalence of oral cancers are expected to increase nearly two-thirds by 2035 especially in younger people due to the popularity of vaping and exposure to HPV.
Initial Screening with AI-Driven Questionnaire
Based on a carefully crafted AI-driven patient questionnaire, extensive epidemiological data, patient history and a clinical examination, patients will be categorized as high or low risk to potentially develop these cancers. Often times based on a patient’s personal history, additional testing will even be advised before any lesions become apparent! Other times, pre-malignant asymptomatic lesions that are visible would also indicate the need for testing. If your initial questionnaire assessment categorizes you as high risk, then molecular saliva testing will be the next most appropriate step.
Take the Oral Cancer Risk Assessment Quiz
About CancerDetect by Viome Life Sciences, Inc
Supporting Medical Literature
Oral Oncology - August 2023 Edition
NPJ Genomic Medicine December 2021